Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11711597 | 0.92 | POLB (0.61) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL5962221 | 0.86 | LMNA (0.67) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL20241012 | 0.85 | KDM4E (0.55) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL3291404 | 0.84 | POLB (0.45) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL21859008 | 0.81 | LMNA (0.54) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL1301511 | 0.79 | POLB (0.42) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL8041564 | 0.79 | POLB (0.69) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL29823822 | 0.79 | POLB (0.69) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL11393030 | 0.79 | POLB (0.69) | LMNAPOLBMAPTKMT2AMEN1 | |
| SCHEMBL30906934 | 0.78 | LMNA (0.63) | LMNAPOLBMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| WO-2018102885-A1 | MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2018-06-14 | — | — | WO | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| EP-2074123-A1 | NOVEL ANXIOLYTIC COMPOUNDS | Bionomics Limited (AU) | 2009-07-01 | — | — | EP | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | LMNA 2733/4885POLB 2580/4885MAPT 2554/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | LMNA 1055/4885POLB 1357/4885MAPT 3397/4885 |
| US-10233181-B2 | Anxiolytic compounds | GABBR1, GABRA6, SLC18A2 | LMNA 2761/4885POLB 3948/4885MAPT 1130/4885 |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | LMNA 4043/4885POLB 4582/4885MAPT 1438/4885 |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | LMNA 4043/4885POLB 4582/4885MAPT 1438/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | LMNA 2879/4885POLB 3815/4885MAPT 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.